Surgery versus Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer
|Editors:||Yaxing Shen, Zhirui Zhou, Qun Wang, Joe Y. Chang, Gaetano Rocco, Alan D. L. Sihoe, Diego Gonzalez-Rivas|
Publisher: AME Publishing Company (2016)
Hardcover: 213 pages
Surgery versus Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer presents to most up to date data available regarding the relative nature, purpose, risks and benefits of the 2 techniques. The current evidence, relevant controversies, and future directions are critically discussed by an international panel of experts, from Asia, Europe, and North America. The editors have compiled more than 25 outstanding contributions that present a fair and balanced treatment of this critically important subject. This book offers a balanced overview of the latest advances in both surgical and SBRT developments. This should hopefully provide the reader with a comprehensive understanding of the current debate, helping guide even better management of our lung cancer patients in the future.
|Qun Wang||Department of Thoracic Surgery, Shanghai Zhongshan Hospital of Fudan University, Shanghai, China|
|Joe Y. Chang||Stereotactic Ablative Radiotherapy, MD Anderson Cancer Center|
|Gaetano Rocco||Director, Department of Thoracic Surgical and Medical Oncology, Chief, Division of Thoracic Surgery, Istituto Nazionale Tumori, Fondazione Pascale, IRCCS, Naples, Italy|
|Alan D. L. Sihoe||Clinical Associate Professor, Department of Surgery, The University of Hong Kong |
Chief of Thoracic Surgery, The University of Hong Kong Shenzhen Hospital
Guest Professor, Department of Thoracic Surgery, Tongji University Shanghai Pulmonary Hospital
|Diego Gonzalez-Rivas||Director Uniportal VATS training program, Shanghai Pulmonary Hospital |
Department of Thoracic Surgery and Lung Transplantation Coruña University Hospital and Minimally
Invasive Thoracic Surgery Unit (UCTMI), Coruña, Spain
|Yaxing Shen||Division of Thoracic Surgery, Zhongshan Hospital of Fudan University, Shanghai, China|
|Zhirui Zhou||Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China|
|Wenzhao Zhong||Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China|
|Yi Pan||Department of Radiation Oncology, Guangdong General Hospital, Guangzhou, China|
|Wenjie Cai||Associate chief physician of Department of Radiotherapy Oncology, First Hospital of Quanzhou, Af liated to Fujian Medical University, Quanzhou, China|
|Guiping Yu||Department of Cardiothoracic Surgery, The Af liated Jiangyin Hospital of Southeast University Medical College, Jiangyin, China|
Table of Content
Preamble to AME Medical Review Series
1 Stereotactic ablative radiotherapy for stage I NSCLC: recent advances and controversies
10 What is the current status of stereotactic body radiotherapy for stage I non-small cell lung cancer?
13 Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer
15 SBRT in operable early stage lung cancer patients
27 Alternatives to surgery in early stage disease—stereotactic body radiotherapy
35 Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy
43 Stereotactic ablative radiotherapy: aim for a cure of cancer
45 Local control rates with five fractions of stereotactic body radiotherapy for primary lung tumors: a single institution experience of 153 consecutive patients
53 Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung
59 Is staging mediastinoscopy necessary before stereotactic body radiotherapy for inoperable early stage lung cancer?
62 A millimeter miss is as good as a thousand miles: The role of accurate target localization in lung stereotactic body radiation therapy
65 Lung stereotactic body radiotherapy (SBRT): a single institution’s outcomes and methodology in the context of a literature review
74 Stereotactic body radiation therapy in lung
88 The factors affecting local tumor control after stereotactic body radiotherapy for non-small cell lung cancer
92 Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy?
Controversy and Debate
102 Stereotactic ablative radiotherapy for stage I NSCLC: Successes and existing challenges
105 Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a word of caution
109 Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage nonsmall cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data
116 Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard
120 Stereotactic ablative radiotherapy and surgery: two gold standards for early-stage non-small cell lung cancer?
124 A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question?
128 The radiobiological targets of SBRT: tumor cells or endothelial cells?
132 Stereotactic ablative body radiotherapy (SABR): an alternative to surgery in stage I-II non-small-cell cancer of the lung?
142 Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?
145 Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?
149 Rebuttal from Ms Woodford and Dr Senthi
151 Rebuttal from Dr Nestle and Dr Belderbos
152 Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future?
157 Stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC): current concepts and future directions
167 Stereotactic ablative radiotherapy (SABR) for lung cancer: what does the future hold?